Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : First Affiliated Hospital of Xinjiang Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 21, 2025
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : First Affiliated Hospital of Xinjiang Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 29, 2024
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 05, 2024
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TNP-2092
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 21, 2023
Lead Product(s) : TNP-2092
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TNP-2092
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 18, 2023
Lead Product(s) : TNP-2092
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TNP-2092 is a multi-targeting drug conjugate, exerting its antibacterial activity by inhibiting three essential targets RNA Polymerase, DNA Gyrase and Topoisomerase IV.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 23, 2021
Lead Product(s) : TNP-2092
Therapeutic Area : Rheumatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 04, 2020
Lead Product(s) : TNP-2092
Therapeutic Area : Rheumatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TenNor Therapeutics Received FDA Orphan Drug Designation
Details : TenNor has completed a Phase II clinical trial for TNP-2092 in the United States for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and received positive results.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 20, 2020
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TNP-2092
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 28, 2019
Lead Product(s) : TNP-2092
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable